Clinical Trials Browser

NCT00019396 2024-03-04

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Phase 2 Completed

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Skin Neoplasms, Urologic Neoplasms

NCT00020267 2024-03-04

Vaccine Therapy in Treating Patients With Metastatic Cancer

Phase 1 Completed

BreastDermatologicGastrointestinalSarcomaThoracic

Uveal Melanoma, Bone Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Eye Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Osteosarcoma, Skin Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Breast Neoplasms, Male, Muscle Neoplasms, Genetic Diseases, Inborn, Histiocytoma, Malignant Fibrous

Clinical Trials

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Vaccine Therapy in Treating Patients With Metastatic Cancer

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Mel-65

Mel63; CHAMP

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

MEL58

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Immunotherapy of Melanoma Patients

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

MEL38